In a report released today, Matthew Harrison from Morgan Stanley maintained a Sell rating on Atea Pharmaceuticals (AVIR – Research Report), with a price target of $7.00. The company’s shares closed last Friday at $8.41.
According to TipRanks, Harrison is a 4-star analyst with an average return of 7.6% and a 52.94% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Regeneron, and Alnylam Pharma.
Currently, the analyst consensus on Atea Pharmaceuticals is a Moderate Sell with an average price target of $9.33.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $46.91 and a one-year low of $5.31. Currently, Atea Pharmaceuticals has an average volume of 624.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atea Pharmaceuticals Inc is a clinical stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company’s medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science.
Read More on AVIR:
- Altisource Asset Management Corporation Announces NYSE Acceptance of Remediation Plan to Address Deficiency Letter Notice
- Southwestern Energy (SWN) Receives a Rating Update from a Top Analyst
- Navitas to Present Next-Gen Semiconductors at Taiwan Investor Fireside Chat
- Raymond James Sticks to Their Buy Rating for MFA Financial (MFA)
- Bitcoin Well Provides an Update on its Outlook for 2022 and Announces Grant of Stock Options